Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 4/20 | 0.60 |
| ▸ | RORC | P51449 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.60 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | POLA1 | P09884 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.50 |
| ▸ | CRYAB | P02511 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9446912 | 0.90 | POLA1 (0.64) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL6903726 | 0.90 | OSBP (0.62) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL7876330 | 0.89 | POLA1 (0.59) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL7876329 | 0.88 | OSBP (0.59) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL7043800 | 0.88 | OSBP (0.66) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL7043798 | 0.88 | OSBP (0.66) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL10334278 | 0.88 | OSBP (0.59) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL4437534 | 0.86 | OSBP (0.59) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL9446923 | 0.86 | POLA1 (0.59) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL9122037 | 0.85 | POLA1 (0.57) | OSBPRORCUSP2CYP46A1OSBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080181928-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | MIV THERAPEUTICS, INC. (CA) | 2008-07-31 | — | — | US | claimed |
| US-11918770-B2 | Implants for localized drug delivery and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220184362-A1 | Implants for Localized Drug Delivery and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-16 | — | — | US | disclosed |
| US-11324935-B2 | Implants for localized drug delivery and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-10 | — | — | US | disclosed |
| US-10912933-B2 | Implants for localized drug delivery and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3183026-B1 | IMPLANTS FOR LOCALIZED DRUG DELIVERY AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190184145-A1 | Implants for Localized Drug Delivery and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-06-20 | — | — | US | disclosed |
| US-20170224970-A1 | Implants for Localized Drug Delivery and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3183026-A1 | IMPLANTS FOR LOCALIZED DRUG DELIVERY AND METHODS OF USE THEREOF | The Regents of The University of California (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016028774-A1 | IMPLANTS FOR LOCALIZED DRUG DELIVERY AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-25 | — | — | WO | disclosed |
| EP-2136856-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | Miv Therapeutics Inc. (CA) | 2009-12-30 | — | — | EP | disclosed |
| US-20080181928-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | MIV THERAPEUTICS, INC. (CA) | 2008-07-31 | — | — | US | disclosed |
| WO-2008077247-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING CHOLESTEROL | MIV THERAPEUTICS INC. (CA) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077248-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | MIV THERAPEUTICS INC. (CA) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181928-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | LIPA, SGMS2, SGMS1 | OSBP 174/4885RORC 2974/4885USP2 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.